2018/01/01 by Toshihide Ogawa, Shinya Fujii, Keita Kuya +4 · 1 citation
Medicine · Neuroscience · #Atrophy #Corticobasal degeneration #Dementia #Dementia with Lewy bodies #Differential diagnosis #Disease #Dopamine #Dopamine transporter #Dopaminergic #Genetic Neurodegenerative Diseases #Internal medicine #Medicine #Neuroimaging #Neurological disorders and treatments #Parkinson's Disease Mechanisms and Treatments #Parkinson's disease #Parkinsonism #Pathology #Progressive supranuclear palsy #Psychiatry #Radiology
paper · pdf · doi:10.33160/yam.2018.09.001
openalex publication_date 2018/01/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/05
An accurate diagnosis of Parkinson’s disease (PD) is a prerequisite for therapeutic management. In spite of recent advances in the diagnosis of parkinsonian disorders, PD is misdiagnosed in between 6 and 25% of patients, even in specialized movement disorder centers. Although the gold standard for the diagnosis of PD is a neuropathological assessment, neuroimaging has been playing an important role in the differential diagnosis of PD and is used for clinical diagnostic criteria. In clinical practice, differential diagnoses of PD include atypical parkinsonian syndromes such as dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, caused by a striatal dopamine deficiency following nigrostrial degeneration. PD may also be mimicked by syndromes not associated with a striatal dopamine deficiency such as essential tremor, drug-induced parkinsonism, and vascular parkinsonism. Moreover, difficulties are associated with the clinical differentiation of patients with parkinsonism from those with Alzheimer’s disease. In this review, we summarize the typical imaging findings of PD and its related diseases described above using morphological imaging modalities (conventional MR imaging and neuromelanin MR imaging) and functional imaging modalities (99mTc-ethyl cysteinate dimer perfusion single photon emission computed tomography, 123I-metaiodobenzylguanidine myocardial scintigraphy, and 123I-FP-CIT dopamine transporter single photon emission computed tomography) that are clinically available in most hospitals. We also attempt to provide a diagnostic approach for the differential diagnosis of PD and its related diseases in clinical practice.